BRIEF—Servier Pharmaceuticals sets out progress in oncology

At the 40th Annual JP Morgan Healthcare Conference, Servier’s new USA-based business, Servier Pharmaceuticals, has highlighted its successes, pointing to a near-20% growth in revenues.

Looking to expand into what is both a new country and a new therapy area for the privately-owned French company, Servier’s US arm got off to a bold start, with the $2 billion acquisition of targeted cancer med firm Agios Pharmaceuticals.

Servier Pharmaceuticals has also doubled its existing workforce and tripled its oncology portfolio with 21 oncology assets at varying stages of clinical development.

The firm has entered the market for the solid tumor therapies with the US Food and Drug Administration approval of Tibsovo (ivosidenib) for IDH1-mutated cholangiocarcinoma.

The company said it has surpassed its 2025 goals ahead of schedule by doubling its oncology portfolio, with four more FDA approvals expected within that timeframe.